Last Updated: May 25, 2026

Details for Patent: 8,772,497


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,772,497 protect, and when does it expire?

Patent 8,772,497 protects FYCOMPA and is included in two NDAs.

This patent has fifty-three patent family members in twenty-eight countries.

Summary for Patent: 8,772,497
Title:Method for producing 1, 2-dihydropyridine-2-one compound
Abstract:The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
Inventor(s):Itaru Arimoto, Satoshi Nagato, Yukiko Sugaya, Yoshio Urawa, Koichi Ito, Hiroyuki Naka, Takao Omae, Akio Kayano, Katsutoshi Nishiura
Assignee: Catalyst Pharmaceuticals Inc
Application Number:US12/870,507
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,772,497
Patent Claim Types:
see list of patent claims
Process;

Drugs Protected by US Patent 8,772,497

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Catalyst Pharms FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Catalyst Pharms FYCOMPA perampanel TABLET;ORAL 202834-001 Oct 22, 2012 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Catalyst Pharms FYCOMPA perampanel TABLET;ORAL 202834-002 Oct 22, 2012 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,772,497

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-198709Jul 6, 2004

International Family Members for US Patent 8,772,497

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1764361 ⤷  Start Trial PA2013017 Lithuania ⤷  Start Trial
European Patent Office 1764361 ⤷  Start Trial C20130021 00081 Estonia ⤷  Start Trial
European Patent Office 1764361 ⤷  Start Trial PA2013017,C1764361 Lithuania ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.